Tags

Type your tag names separated by a space and hit enter

EFTUD2 missense variants disrupt protein function and splicing in mandibulofacial dysostosis Guion-Almeida type.
Hum Mutat. 2020 08; 41(8):1372-1382.HM

Abstract

Pathogenic variants in the core spliceosome U5 small nuclear ribonucleoprotein gene EFTUD2/SNU114 cause the craniofacial disorder mandibulofacial dysostosis Guion-Almeida type (MFDGA). MFDGA-associated variants in EFTUD2 comprise large deletions encompassing EFTUD2, intragenic deletions and single nucleotide truncating or missense variants. These variants are predicted to result in haploinsufficiency by loss-of-function of the variant allele. While the contribution of deletions within EFTUD2 to allele loss-of-function are self-evident, the mechanisms by which missense variants are disease-causing have not been characterized functionally. Combining bioinformatics software prediction, yeast functional growth assays, and a minigene (MG) splicing assay, we have characterized how MFDGA missense variants result in EFTUD2 loss-of-function. Only four of 19 assessed missense variants cause EFTUD2 loss-of-function through altered protein function when modeled in yeast. Of the remaining 15 missense variants, five altered the normal splicing pattern of EFTUD2 pre-messenger RNA predominantly through exon skipping or cryptic splice site activation, leading to the introduction of a premature termination codon. Comparison of bioinformatic predictors for each missense variant revealed a disparity amongst different software packages and, in many cases, an inability to correctly predict changes in splicing subsequently determined by MG interrogation. This study highlights the need for laboratory-based validation of bioinformatic predictions for EFTUD2 missense variants.

Authors+Show Affiliations

Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.Laboratory of Embryology and Genetics of Human Malformation, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Institut Imagine, Paris, France. Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, Paris, France.Laboratory of Embryology and Genetics of Human Malformation, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Institut Imagine, Paris, France. Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, Paris, France. Département de Génétique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, Paris, France. Département de Génétique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France. INSERM UMR 1163, Institut Imagine, Paris, France.Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.All Wales Medical Genomics Service, Cardiff, UK.Laboratory of Embryology and Genetics of Human Malformation, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Institut Imagine, Paris, France. Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, Paris, France. Département de Génétique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Center for Genomic Medicine, St. Mary's Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32333448

Citation

Thomas, Huw B., et al. "EFTUD2 Missense Variants Disrupt Protein Function and Splicing in Mandibulofacial Dysostosis Guion-Almeida Type." Human Mutation, vol. 41, no. 8, 2020, pp. 1372-1382.
Thomas HB, Wood KA, Buczek WA, et al. EFTUD2 missense variants disrupt protein function and splicing in mandibulofacial dysostosis Guion-Almeida type. Hum Mutat. 2020;41(8):1372-1382.
Thomas, H. B., Wood, K. A., Buczek, W. A., Gordon, C. T., Pingault, V., Attié-Bitach, T., Hentges, K. E., Varghese, V. C., Amiel, J., Newman, W. G., & O'Keefe, R. T. (2020). EFTUD2 missense variants disrupt protein function and splicing in mandibulofacial dysostosis Guion-Almeida type. Human Mutation, 41(8), 1372-1382. https://doi.org/10.1002/humu.24027
Thomas HB, et al. EFTUD2 Missense Variants Disrupt Protein Function and Splicing in Mandibulofacial Dysostosis Guion-Almeida Type. Hum Mutat. 2020;41(8):1372-1382. PubMed PMID: 32333448.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - EFTUD2 missense variants disrupt protein function and splicing in mandibulofacial dysostosis Guion-Almeida type. AU - Thomas,Huw B, AU - Wood,Katherine A, AU - Buczek,Weronika A, AU - Gordon,Christopher T, AU - Pingault,Véronique, AU - Attié-Bitach,Tania, AU - Hentges,Kathryn E, AU - Varghese,Vinod C, AU - Amiel,Jeanne, AU - Newman,William G, AU - O'Keefe,Raymond T, Y1 - 2020/05/03/ PY - 2020/01/14/received PY - 2020/03/26/revised PY - 2020/04/19/accepted PY - 2020/4/26/pubmed PY - 2021/11/9/medline PY - 2020/4/26/entrez KW - EFTUD2 KW - Snu114 KW - mandibulofacial dysostosis Guion-Almeida type KW - minigene KW - missense variants KW - pre-mRNA splicing KW - splicing variants KW - yeast SP - 1372 EP - 1382 JF - Human mutation JO - Hum Mutat VL - 41 IS - 8 N2 - Pathogenic variants in the core spliceosome U5 small nuclear ribonucleoprotein gene EFTUD2/SNU114 cause the craniofacial disorder mandibulofacial dysostosis Guion-Almeida type (MFDGA). MFDGA-associated variants in EFTUD2 comprise large deletions encompassing EFTUD2, intragenic deletions and single nucleotide truncating or missense variants. These variants are predicted to result in haploinsufficiency by loss-of-function of the variant allele. While the contribution of deletions within EFTUD2 to allele loss-of-function are self-evident, the mechanisms by which missense variants are disease-causing have not been characterized functionally. Combining bioinformatics software prediction, yeast functional growth assays, and a minigene (MG) splicing assay, we have characterized how MFDGA missense variants result in EFTUD2 loss-of-function. Only four of 19 assessed missense variants cause EFTUD2 loss-of-function through altered protein function when modeled in yeast. Of the remaining 15 missense variants, five altered the normal splicing pattern of EFTUD2 pre-messenger RNA predominantly through exon skipping or cryptic splice site activation, leading to the introduction of a premature termination codon. Comparison of bioinformatic predictors for each missense variant revealed a disparity amongst different software packages and, in many cases, an inability to correctly predict changes in splicing subsequently determined by MG interrogation. This study highlights the need for laboratory-based validation of bioinformatic predictions for EFTUD2 missense variants. SN - 1098-1004 UR - https://www.unboundmedicine.com/medline/citation/32333448/EFTUD2_missense_variants_disrupt_protein_function_and_splicing_in_mandibulofacial_dysostosis_Guion_Almeida_type_ DB - PRIME DP - Unbound Medicine ER -